EP0923605A4 - Conjugated mucin peptide vaccines - Google Patents

Conjugated mucin peptide vaccines

Info

Publication number: EP0923605A4
Authority: EP; European Patent Office
Prior art keywords: peptide vaccines; mucin peptide; conjugated; conjugated mucin; vaccines
Prior art date: 1996-03-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP97916865A

Other languages

German (de)

French (fr)

Other versions

EP0923605A1 (en

Inventor

Philip O Livingston

Shengle Zhang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Memorial Sloan Kettering Cancer Center

Original Assignee

Sloan Kettering Institute for Cancer Research

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-20

Filing date

1997-03-20

Publication date

2003-01-02

1997-03-20 Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research

1999-06-23 Publication of EP0923605A1 publication Critical patent/EP0923605A1/en

2003-01-02 Publication of EP0923605A4 publication Critical patent/EP0923605A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

EP97916865A 1996-03-20 1997-03-20 Conjugated mucin peptide vaccines Withdrawn EP0923605A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1377596P	1996-03-20	1996-03-20
PCT/US1997/004493 WO1997034921A1 (en)	1996-03-20	1997-03-20	Conjugated mucin peptide vaccines
US13775P		2007-12-14

Publications (2)

Publication Number	Publication Date
EP0923605A1 EP0923605A1 (en)	1999-06-23
EP0923605A4 true EP0923605A4 (en)	2003-01-02

Family

ID=21761689

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP97916865A Withdrawn EP0923605A4 (en)	1996-03-20	1997-03-20	Conjugated mucin peptide vaccines

Country Status (5)

Country	Link
EP (1)	EP0923605A4 (en)
JP (1)	JP2001510440A (en)
AU (1)	AU734253B2 (en)
CA (1)	CA2249395A1 (en)
WO (1)	WO1997034921A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6410507B1 (en)	1997-12-24	2002-06-25	Corixa Corporation	Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US6379951B1 (en)	1997-12-24	2002-04-30	Corixa Corporation	Compounds for immunotherapy of breast cancer and methods for their use
US6432707B1 (en)	1997-12-24	2002-08-13	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
WO1999033869A2 (en) *	1997-12-24	1999-07-08	Corixa Corporation	Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
US6468758B1 (en)	1998-09-23	2002-10-22	Corixa Corporation	Compositions and methods for ovarian cancer therapy and diagnosis
GB9904695D0 (en) *	1999-03-01	1999-04-21	Imp Cancer Res Tech	Peptide
GB9930359D0 (en) *	1999-12-22	2000-02-09	Glaxo Group Ltd	Novel polypeptides
ES2424131T3 (en)	2001-03-27	2013-09-27	Oncothyreon Inc.	Vaccine to modulate immune responses between T1 and T2
JP2005530494A (en) *	2002-04-22	2005-10-13	リコファーマアーベー	Lewis Y epitope variant polypeptide, or mucin fusion polypeptide, tumor vaccine
TWI395591B (en) *	2004-04-01	2013-05-11	Oncothyreon Inc	Mucinous glycoprotein (muc-1) vaccine
AU2006274651B2 (en)	2005-06-28	2012-09-27	Oncothyreon Inc.	Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
JP2014518841A (en)	2011-02-24	2014-08-07	オンコシレオンインク．	MUC1-based glycolipopeptide vaccine with adjuvant
ES2811523T3 (en)	2016-01-19	2021-03-12	Pfizer	Cancer vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995003825A1 (en) *	1993-07-30	1995-02-09	Finn Olivera J	Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5229289A (en) *	1988-03-11	1993-07-20	The Biomembrane Institute	Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
US5455034A (en) *	1992-06-26	1995-10-03	Kansas State University Research Foundation	Fusobacterium necrophorum leukotoxoid vaccine

1997
- 1997-03-20 WO PCT/US1997/004493 patent/WO1997034921A1/en not_active Application Discontinuation
- 1997-03-20 AU AU25369/97A patent/AU734253B2/en not_active Ceased
- 1997-03-20 EP EP97916865A patent/EP0923605A4/en not_active Withdrawn
- 1997-03-20 JP JP53370097A patent/JP2001510440A/en active Pending
- 1997-03-20 CA CA002249395A patent/CA2249395A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995003825A1 (en) *	1993-07-30	1995-02-09	Finn Olivera J	Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
APOSTOLOPOULOS ET AL: "The immunogenicity of MUC1 peptides and fusion protein", CANCER LETTERS, NEW YORK, NY, US, vol. 90, no. 1, 23 March 1995 (1995-03-23), pages 21 - 26, XP002093264, ISSN: 0304-3835 *
APOSTOLOPOULOS V ET AL: "Breast cancer immunotherapy: current status and future prospects.", IMMUNOLOGY AND CELL BIOLOGY, (1996 OCT) 74 (5) 457-64. REF: 41 JOURNAL CODE: GH8. ISSN: 0818-9641., Australia, XP002097415 *
APOSTOLOPOULOS V ET AL: "Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.", VACCINE, (1996 JUN) 14 (9) 930-8. JOURNAL CODE: X6O. ISSN: 0264-410X., ENGLAND: United Kingdom, XP002097414 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MA, YUNGUO ET AL: "Anti- tumor activity and immune responses induced by human cancer -associated mucin core peptide", XP002215905, retrieved from STN Database accession no. 127:204445 CA *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; IMAI K: "New mucin core protein genes and their clinical application.", XP002215904, retrieved from STN Database accession no. 96202240 *
GULLICK W J: "Production of antisera to synthetic peptides.", METHODS IN MOLECULAR BIOLOGY, (1994) 32 389-99. REF: 22 JOURNAL CODE: BU3. ISSN: 1064-3745., United States, XP002097418 *
HOKKAIDO IGAKU ZASSHI. HOKKAIDO JOURNAL OF MEDICAL SCIENCE, (1996 MAR) 71 (2) 139-43. REF: 9 *
LIVINGSTON, P. ET AL: "Antibody response to vaccination of breast cancer patients with MUC1-KLH plus QS-21 is restricted to the APDTRPA epitope.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (1997) VOL. 38, NO. 0, PP. 396. MEETING INFO.: EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH SAN DIEGO, CALIFORNIA, USA APRIL 12-16, 1997 ISSN:, XP002097416 *
See also references of WO9734921A1 *
SPICER, A. P. ET AL: "Analysis of mammalian MUC1 genes reveals potential functionally important domains", MAMM. GENOME (1995), 6(12), 885-8 CODEN: MAMGEC;ISSN: 0938-8990, 1995, XP002097417 *
XING P-X ET AL: "SECOND-GENERATION MONOCLONAL ANTIBODIES TO INTESTINAL MUC2 PEPTIDE REACTIVE WITH COLON CANCER.", J NATL CANCER INST (BETHESDA), (1992) 84 (9), 699-703., XP002215903 *
XING, PEI-XIANG ET AL: "Phase I study of synthetic MUC1 peptides in breast cancer.", INTERNATIONAL JOURNAL OF ONCOLOGY, (1995) VOL. 6, NO. 6, PP. 1283-1289. ISSN: 1019-6439., XP002097412 *
ZHANG S ET AL: "Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.", CANCER RESEARCH, (1996 JUL 15) 56 (14) 3315-9. JOURNAL CODE: CNF. ISSN: 0008-5472., United States, XP002097413 *
ZHONGHUA ZHONGLIU ZAZHI (1996), 18(6), 419-421, 1996 *

Also Published As

Publication number	Publication date
EP0923605A1 (en)	1999-06-23
AU2536997A (en)	1997-10-10
CA2249395A1 (en)	1997-09-25
JP2001510440A (en)	2001-07-31
AU734253B2 (en)	2001-06-07
WO1997034921A1 (en)	1997-09-25

Publication	Publication Date	Title
EG24292A (en)	2009-01-08	Interferon conjugates
GB9620795D0 (en)	1996-11-20	Vaccines
EP0958373A4 (en)	2001-11-28	Vaccines
PL330348A1 (en)	1999-05-10	Peptidic derivatives
EP0923605A4 (en)	2003-01-02	Conjugated mucin peptide vaccines
PL328486A1 (en)	1999-02-01	Peptidic derivatives
AU5763998A (en)	1998-07-17	Chlamydia vaccines
GB9624562D0 (en)	1997-01-15	Peptide derivatives
GB2331521B (en)	2000-09-06	Vaccine preparations
EP0935608A4 (en)	2004-09-15	Cytotoxic peptides
GB9625968D0 (en)	1997-01-29	Vaccine
GB9609252D0 (en)	1996-07-03	Vaccines
GB9606765D0 (en)	1996-06-05	Peptides
GB9605904D0 (en)	1996-05-22	Peptides
SG55039A1 (en)	1998-12-21	Peptides
GB9626362D0 (en)	1997-02-05	Peptides
GB9625227D0 (en)	1997-01-22	Peptides
GB9612648D0 (en)	1996-08-21	Peptides
GB9608430D0 (en)	1996-06-26	Peptides
GB9709607D0 (en)	1997-07-02	Peptide derivatives
GB9611881D0 (en)	1996-08-07	Peptide derivatives
GB9603855D0 (en)	1996-04-24	Peptide derivatives
SI0882066T1 (en)	2000-12-31	Peptide derivatives
GB9625967D0 (en)	1997-01-29	Vaccine
GB9625966D0 (en)	1997-01-29	Vaccine

Legal Events

Date	Code	Title	Description
1999-05-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1999-06-23	17P	Request for examination filed	Effective date: 19981020
1999-06-23	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-01-02	A4	Supplementary search report drawn up and despatched	Effective date: 20021108
2003-01-02	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2004-01-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN
2004-03-10	18W	Application withdrawn	Effective date: 20040115